Benjamin Garmezy, MD

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Abbvie
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Accutar
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Arcus
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    AstraZeneca
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    AVEO
    Topic:
    Research Funding and Consulting - Institution
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    CRISPR Therapeutics
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Exelixis
    Topic:
    Research Funding and Consulting - Institution
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Genetech/Roche
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    Harbour BioMed
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023
  • Attribution:
    Other
    Type of financial relationship:
    Other
    Ineligible company:
    IDEAYA Biosciences
    Topic:
    Research Funding
    Date added:
    09/13/2023
    Date updated:
    09/13/2023

Pages

Return to PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice